
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc has demonstrated a robust growth trajectory, with orders growing 16% year-over-year in fiscal year 2024, indicating strong demand for its electrotherapy and pain management products. The company's focus on innovation, highlighted by the positive results from the NiCo verification clinical study, suggests that its advanced laser-based system may outperform existing solutions in the market, further enhancing its competitive edge. Additionally, projected operational cost reductions of approximately $35 million annually and goals to improve revenue per sales representative bolster the company’s financial efficiency and growth potential, underpinning a positive outlook for its stock.
Bears say
Zynex Inc. is facing a significant downward trend in its financial performance, as evidenced by its projected Q1 2025 sales of at least $30 million, indicating a decline of 37% year-over-year and a 35% sequential decrease. The company reported a total revenue of $46 million for Q4 2024, which was a 3% decline from the previous year and fell short of projections by $8 million, with disappointing device sales dropping by 9%. Furthermore, the outlook for 2025 has worsened considerably, with expected sales reduced to $140 million from a prior estimate of $241 million, reflecting a notable lack of visibility into the company's operational health and ongoing business headwinds.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares